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Abstract
A decrease in the incidence of human immune deficiency virus-associated Kaposi sarcoma (HIV-
KS) and regression of some established HIV-KS lesions is evident after the introduction of highly
active anti-retroviral treatment (HAART), and is attributed to generalized immune restoration, to
the reconstitution of human herpesvirus (HHV)-8 specific cellular immune responses, and to the
decrease in HIV Tat protein and HHV-8 loads following HAART. However, a small subset of HIV-
seropositive subjects with a low CD4+ T cell count at the time of introduction of HAART, may
develop HIV-KS as immune reconstitution inflammatory syndr o m e  ( I R I S )  w i t h i n  8  w e e k s
thereafter.
Introduction
Kaposi sarcoma (KS) is the most common human immu-
nodeficiency virus (HIV)-associated neoplasm [1]. HIV-
associated Kaposi sarcoma (HIV-KS) lesions are character-
ized microscopically by angiogenesis, the presence of
spindle-shaped tumour cells, inflammatory cell infiltrates
dominated by mononuclear cells, extravasated erythro-
cytes and oedema [2-4]. Clinically, HIV-seropositive sub-
jects with KS exhibit mainly multifocal mucocutaneous
patches, plaques and nodules, and less frequently organ
involvement [5-7]. The most common site of extra-muco-
cutaneous HIV-KS involvement is the lymph nodes fol-
lowed by the gastro-intestinal tract and the lungs. The oral
cavity is commonly affected and is the initial site of
involvement with KS in about 20% of HIV-seropositive
subjects with KS [8]. Oedema is a major clinical feature
associated with advanced KS. It results most frequently
when a local inflammatory reaction induced by produc-
tion of cytokines by KS cells is complicated either by lym-
phatic obstruction by the enlarging tumour itself, or less
commonly by proximal lymph node involvement [9]. The
pathogenesis of HIV-KS is complex, and involves interac-
tion between human herpesvirus (HHV)-8, HIV, inflam-
matory cytokines, and angiogenic factors in the presence
of profound immune suppression [10-12]. However, the
understanding of how these multiple factors interplay to
initiate KS is incomplete [3].
HHV-8 is present in all four epidemiological forms of KS
(classic, endemic, iatrogenic and HIV-KS). Seroprevalence
studies demonstrate that HHV-8 DNA in peripheral blood
mononuclear cells (PBMC) and specific antibodies to
HHV-8 are associated with increased risk of KS, and there
is a positive correlation between the HHV-8 viral load and
the severity of KS. These lines of evidence indicate that
HHV-8 is necessary for the development of KS, but since
HHV-8 seroconversion in the general population is not
uncommon and is much more common in HIV-seroposi-
tive subjects, but yet only some members of these popula-
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tions develop KS, other co-factors are clearly necessary for
the development of KS [13-29].
HIV contributes to the pathogenesis of KS through several
mechanisms: HIV Tat protein directly promotes HHV-8
replication [30,31]; HIV induces the production of
inflammatory cytokines [12,32], and causes a profound
immune impairment that is conducive to the develop-
ment of KS. The incidence and aggressiveness of KS is sub-
stantially increased in HIV-seropositive subjects
compared to HIV-seronegative subjects [10,31,32]. This
emphasizes the important role of HIV in the natural
course of HIV-KS.
The use of highly active antiretroviral therapy (HAART)
has resulted in a dramatic reduction in the morbidity and
mortality in HIV-seropositive subjects [33-36]. HAART,
although not directly affecting HHV-8 replication, indi-
rectly brings about a decrease in HHV-8 viral load [37], a
substantial reduction in the prevalence and incidence of
HIV-KS [38-42], and improvement in the clinical manifes-
tation of KS [43-52].
However, HAART does not ensure that KS will not
develop, and in subjects receiving HAART, KS remains the
most frequent HIV-associated neoplasm [5,53]. HIV-sero-
positive subjects who had already received HAART at the
time of KS diagnosis, usually have less aggressive KS dis-
ease compared to HIV-seropositive subjects who were
HAART naïve at the time of KS diagnosis [5,54]. In addi-
tion, KS sometimes recrudesces as an immune reconstitu-
tion inflammatory syndrome (IRIS) in HIV-seropositive
subjects shortly after the introduction of HAART, despite
an improvement in the CD4+ T cell count and controlled
HIV viremia [55-60].
The natural course of HIV-KS
There is a compelling body of information that supports
the concept that HIV-KS is an opportunistic tumour that
starts as a reactive hyperplasia and eventually may
progress to a true neoplasia [12,13,16,23,60-64].
HIV-KS has its origin in an environment induced by
inflammatory T helper (Th)-1 cytokines associated with a
marked impairment of cellular immune responses,
brought about by HIV infection. The inflammatory infil-
trate in HIV-KS lesions comprise CD8+ T cells, monocytes,
macrophages and dendritic cells. These cells produce
inflammatory cytokines that together with HHV-8 gene
products, activate endothelial cells and trigger the devel-
opment of HIV-KS. Early HIV-KS lesions manifest clini-
cally as indolent red-purple macules or papules, that show
proliferation of endothelial cells and formation of slit-
shaped vascular channels resembling well vascularized
exuberant granulation tissue. In time, HIV-KS lesions
become nodular and may have an aggressive clinical
behaviour [60,61].
The late-stage maculo-papular HIV-KS lesions are charac-
terized by proliferation of spindle cells, of lymphatic and/
or blood vascular endothelial origin. The spindle cells
become the predominant cell type, though the vascular
element is always evident [23,65,66]. The progression of
HIV-KS is attributed to dysregulation in cell cycle growth
and resistance to apoptotic signals mediated by altered
cytokine networks, latent and dysregulated lytic HHV-8
genes and HIV Tat protein [3,67].
Early-stage HIV-KS is a polyclonal reactive angioprolifera-
tive disorder. This is evident from the multifocal charac-
teristic of the HIV-KS lesions in the absence of metastasis;
by the occasional regression of HIV-KS lesions either
spontaneously or following the introduction of HAART;
and by the lack of clonality [68]. In contrast, late stage
HIV-KS lesions from disparate subjects may show a spec-
trum of multiclonal origin, monoclonality, oligoclonality
and polyclonality, and it is likely that a subset of late-stage
lesional cells of monoclonal origin undergo malignant
transformation [69,70].
Most of HIV-KS spindle cells express HHV-8 latent genes,
but not genes that are involved in lytic reactivation and
replication of latently infected cells. However, some of the
virally infected KS cells express HHV-8 lytic genes, that
provide paracrine angioproliferative inductive signals to
neighbouring endothelial and spindle cells mediating
angiogenesis and spindle cell proliferation [23].
The persistent endothelial and spindle cell proliferation,
in response to HHV-8 induced inflammatory and growth
factors, and to HHV-8 oncogenes leads to dysregulated
cell proliferation and survival, followed by cellular trans-
formation and eventual progression to a monoclonal
tumour [12,13,23]. The malignant transformation of HIV-
KS cells, when and if it occurs, is probably driven by HHV-
8 latent oncogenes and by the dysregulated constitutive
activity of viral G protein-coupled receptor (vGPCR)
expressed outside the lytic phase of the virus replication
cycle, without notable cellular genetic and epigenetic
mutation of cell cycle genes and/or tumour suppressor
genes [3,62].
The implication of inflammatory cytokines in the 
pathogenesis of HIV-KS
The pathogenesis of HIV-KS is related to infection with
HHV-8 and HIV, and to persistent inflammation in the
presence of high level of Th1-type inflammatory cytokines
including tumour necrosis factor (TNF)-α, interferon
(INF)-γ, interleukin (IL)-1β, and IL-6, within an environ-
ment of immunosuppression. Increased HIV and HHV-8Infectious Agents and Cancer 2008, 3:1 http://www.infectagentscancer.com/content/3/1/1
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loads and concurrent opportunistic infections only serve
to perpetuate the inflammatory state [60,71]. It is proba-
ble that the increased level of inflammatory and ang-
iogenic cytokines in all epidemiological forms of KS is the
consequence of the local host immune activation against
HHV-8 and the HHV-8 release of cytokines in response to
the output of the HHV-8 genes [11,13].
High levels of inflammatory cytokines in early KS lesions
trigger endothelial cells to express activation markers
including vascular cell adhesion molecules, matrix metal-
loproteinase (MMP), α5β1 and αVβ3 integrins, growth fac-
tors such as vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (bFGF), and inflamma-
tory and angiogenic cytokines acting in both paracrine
and autocrine manner. These activated endothelial cells
acquire abnormal phenotypic and functional features
(angiogenic phenotype) that may initiate and promote
the development of HIV-KS [61].
Inflammatory cytokines have the capacity to reactivate
latent HHV-8, resulting in an increase of HHV-8 plasma
load and spread of HHV-8 in tissues, and to promote HIV
replication, leading to a further production of HIV Tat
protein and deterioration in host immune responses.
Thus, inflammatory cytokines have the potential to per-
petuate an environment conducive to HIV-KS initiation
and progression [61].
α5β1 and αVβ3 integrins
The interactions between cells and extracellular matrix
molecules (ECM) are mediated by cell membrane recep-
tors belonging to the integrin family, that mediate cellular
migration and growth [72,73]. The increased levels of
inflammatory cytokines and bFGF found in HIV-KS
lesions upregulate the expression of α5β1  and  αVβ3
integrins on HIV-KS cells [74].
In HIV-seropositive subjects, extracellular HIV Tat protein
binds to α5β1 and αVβ3 integrin receptors on KS endothe-
lial and spindle cells, to provide them with the necessary
signals for adhesion that is required for their subsequent
proliferation in response to mitogenic stimuli by bFGF.
HIV Tat protein also induces the synthesis of MMP-2 and
MMP-9. The increased expression of MMPs in HIV-KS
cells may lead to degradation of extracellular matrix com-
ponents, facilitating the locomotion of endothelial cells
and invasion of spindle cells [61,74,75].
In HIV-seronegative subjects with KS, cellular growth and
migration, and the expression of MMPs are induced by
(α5β1)-fibronectin and (αVβ3)-vitronectin interactions in
the presence of bFGF. The presence of HIV Tat protein in
HIV-KS fortifies the α5β1 and αVβ3 stimulation [76,77].
This might explain the increased frequency of KS and the
greater aggressiveness in clinical behaviour of HIV-KS
compared to other epidemiological forms of KS.
The role of bFGF and VEGF in the pathogenesis 
of HIV-KS
VEGF and bFGF are angiogenic growth factors that are
powerfully expressed in HIV-KS lesions and promote ang-
iogenesis. Both induce MMPs production by endothelial
cells, and vascular permeability and subsequently oedema
that is an important feature of HIV-KS [74,78]. bFGF is
produced by immunoregulatory cells, that are present in
HIV-KS lesions, and by activated endothelial cells [79,80].
bFGF has an instrumental role in the development of HIV-
KS. It can initiate and sustain neovascularization by pro-
viding mitogenic signals to activated endothelial cells and
spindle cells [32,60,81]. This concept is supported by
reports that the expression of bFGF is upregulated in HIV-
KS spindle cells, and antibodies to bFGF mRNA substan-
tially reduce the angiogenic and proliferative potential of
HIV-KS cells [71]. In HIV-seropositive subjects with KS,
bFGF mediates Tat-induced endothelial cell proliferation,
and acts with HIV Tat in promoting the production of
MMPs by endothelial cells[72,82].
VEGF is a potent specific endothelial cell mitogen pro-
duced by HIV-KS endothelial and spindle cells in response
to inflammatory cytokines that induce angiogenesis
through autocrine mechanisms [23,83]. VEGF can syner-
gise with bFGF to induce vascular permeability and
oedema, and angiogenesis [13,23], and it is expressed and
upregulated by several HHV-8 proteins including vIL-6
and vGPCR and plays a significant part in the develop-
ment of KS [65].
MMPs
MMPs are a family of proteolytic enzymes involved in
degradation of extracellular matrix and basement mem-
brane components. MMP gene expression is induced by a
variety of stimuli including inflammatory cytokines,
ECM-integrin interaction, growth factors, HIV Tat protein
and HHV-8 proteins [13,65,75]. MMP-2 is upregulated in
HIV-KS lesions and it may play a rôle in inducing vascular
permeability and oedema and in promoting endothelial
cell growth, angiogenesis and tumour invasion
[74,84,85].
Oxidative and nitrative metabolites in the 
pathogenesis of HIV-KS
Persistent inflammatory state is conducive to the produc-
tion of ongoing reactive oxidative and nitrative metabo-
lites which are associated with tumourgenesis. They
promote cell proliferation, initiate nuclear and mitochon-
drial DNA mutations, induce a proangiogenic environ-
ment, and inactivate DNA repair enzymes [71,86].Infectious Agents and Cancer 2008, 3:1 http://www.infectagentscancer.com/content/3/1/1
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HIV-seropositive subjects have high tissue levels of reac-
tive oxidative and nitrative metabolites owing to
increased levels of proinflammatory cytokines, more fre-
quent opportunistic infections and a reduction in the
activity of antioxidant enzymes [87]. HIV-KS lesional cells
express endogenous oxidative and nitrative metabolites
which together with increased exogenous oxidative and
nitrative metabolite levels, associated with HIV infection,
may promote the particular aggressiveness of KS in HIV-
seropositive subjects [71].
HIV infection, HAART and KS
HIV infection may directly and indirectly promote the ini-
tiation and progression of KS. HIV Tat protein, a transcrip-
tional activator of HIV gene expression, is a major factor
implicated in the pathogenesis of HIV-KS [82]. Tat protein
is released by HIV-infected T cells. In this extracellular
form, Tat synergises with inflammatory cytokines, which
are upregulated in HIV-KS lesions, to promote angiogen-
esis, and progression of HIV-KS. It does this by the induc-
tion and mobilization of bFGF, and by interacting with
α5β1 and αVβ3 integrins on both endothelial and spindle
cells [75,80]. The coordinated signalling to endothelial
cells integrins α5β1 and αVβ3 and growth factor receptors
by Tat protein and bFGF respectively, are important events
in the pathogenesis of HIV-KS [12,76].
By binding to α5β1 and αVβ3 integrins on inflammatory
cytokine-activated endothelial cells, Tat protein activates
the cascade of events in the FAS-ERK-MAPK intracellular
signal transduction pathway. This promotes the progres-
sion of KS endothelial cells through the G1 cell cycle
phase in response to bFGF stimulation, and results in
increased cell proliferation [76]. In addition, Tat protein
may act as an antiapoptotic agent causing prolonged sur-
vival of endothelial cells [67]. It also has the capacity to
regulate the cycle of HHV-8 growth and to reactivate latent
HHV-8 infection [9,13]. A further outcome of the activity
of Tat protein can be an increase in the synthesis of MMP-
2 by monocytes and by endothelial cells leading to
increased vascular permeability and oedema [74].
HIV infection may indirectly affect the course of HIV-KS
by perpetuating immunosuppression and immunodys-
regulation, characterized by increased production of
proinflammatory cytokines that sustain the KS [13].
Moreover, Tat protein induces in monocyte-derived den-
dritic cells an increase in production of Th1 type cytokines
and β chemokines [77].
Following the introduction of HAART sometimes estab-
lished HIV-KS may regress and the likelihood of develop-
ing new lesions of KS is diminished [5,9,13,38,40]. This
can be attributed to three factors. Firstly, the reduction in
HIV load, Tat protein and inflammatory cytokines [13],
secondly, HHV-8 specific – CD8 + cytotoxic T lymphocyte
response is improved following HAART [13,88,89] and
therefore there is a reduction in HHV-8 load. Thirdly,
some protease inhibitors that are administered as a com-
ponent of HAART have anti-inflammatory and anti-ang-
iogenic activity, thus directly inhibiting HIV-KS [10].
However, despite otherwise effective HAART, established
HIV-KS may not always regress, and new KS lesions may
appear [13,54], perhaps as a manifestation of immune
reconstitution inflammatory syndrome (IRIS)
[30,33,55,56,59].
HIV associated IRIS
IRIS can be defined as an exuberant immune-mediated
inflammatory response to a pre-existing subclinical path-
ogen or tumour antigen after treatment has brought about
an improvement in a host previously profoundly
depressed immunity [55,59,90]. In the context of HIV
infection, HAART-induced IRIS has been described in rela-
tion to opportunistic infections including herpes simplex
(HS), herpes zoster (HZ), mycobacterium tuberculosis, in
relation to autoimmune thyroid disease, and in relation
to KS. HIV-IRIS occurs paradoxically despite a reduction
in HIV load and improvement in all HIV related immuno-
logic parameters early after the introduction of HAART,
and is probably the result of reconstituted pathogen-spe-
cific immune responses [33,89,91-96]. However, the
details regarding the immunopathogenic mechanisms
that bring about IRIS are speculative [96].
In HIV-seropositive subjects who start HAART at an early
stage of HIV infection, the number and function of CD4+
T cells tend to return to normal. On the other hand, sub-
jects who start HAART, when the HIV infection is moder-
ately advanced (CD4+ T cell counts are between 100 ×
106/L and 300 × 106/L), will not show a similar recovery.
However, even such a partial immune reconstitution
results in a profound decline in HIV-associated morbidity
and mortality [97].
CD4+ T cell restoration in peripheral blood after HAART
is biphasic. An initial rapid increase during the first 12
weeks of treatment is followed by a more gradual increase
over the remainder of the first year, and after that there is
usually no further significant improvement. The initial-
phase increase in the CD4+ T cells is due to proliferation
and reduced apoptosis of existing memory cells in the cir-
culation and to redistribution of CD4+ T cells from the
lymph nodes into the circulation. Only after several
months of HAART, will T lymphoiesis associated with
improvement of thymic function become evident, giving
rise to increased numbers of naïve T lymphocytes [89,97-
105]. With continued HAART there will also be an
increase in CD8+ T cells in the circulation lagging behindInfectious Agents and Cancer 2008, 3:1 http://www.infectagentscancer.com/content/3/1/1
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the peak increase in CD4+ T cells by a period of about 5
weeks. During the initial immune reconstitution phase
the ability of the host to mount immuno-inflammatory
responses is restored [33,106], owing to the partial recov-
ery of CD4+ T cells and CD8+ cytotoxic T cell responses,
and the shift from a Th-2- to a Th-1-dominant cytokine
profile.
All HIV-IRIS events occur in subjects who display as indi-
cators of immune reconstitution, a decrease in HIV viral
load and an increase in CD4+ T cell count. HIV-seroposi-
tive subjects with IRIS episodes tend to be younger at the
time of introduction of HAART and tend to have a lower
median baseline CD4+ T cell percentage than HIV-serop-
ositive subjects who do not experience IRIS. Overall, the
median time to onset of IRIS in those subjects who display
this response is 12 weeks [92-96].
HIV-seropositive subjects who are at greater risk for devel-
oping IRIS are those with low CD4+ T cell counts of < 100
cells/ul [95,107], those with CD4+ T cell percentage of
<10%, and those of a younger age at the time of introduc-
tion of HAART [96]. There is no association between the
risk for developing IRIS and the magnitude of the increase
in CD4+ T cell count or the percentage of CD4+ T cell
increase, and the plasma load decrease following HAART
[95,96,108] In contrast, Shelburne et al.[94] and Breton et
al.[109] found that HIV-IRIS is associated with a greater
increase in the percentage of CD4+ T cell one month after
the introduction of HAART and with a more pronounced
and persistent reduction in HIV load. Thus, there is some
conflict in the immunological parameters associated with
the development of HIV-IRIS.
The definite association of the events of HIV-IRIS with a
low baseline CD4+ T cell percentage probably reflects a
higher burden of opportunistic subclinical pathogens at
the time of HAART introduction. Such a high burden of
antigenic stimulation together with a dysregulated
increased immune response during immunoreconstitu-
tion after HAART, may be responsible for the develop-
ment of HIV-IRIS [90].
The immunopathogenic mechanisms associated with IRIS
differ according to the type of pathogen involved [90].
CD8+ cytotoxic T cell response is associated with IRIS
induced by viral infections [110,111] and a delayed type-
hypersensitivity or a lymphoproliferative reaction with
IRIS induced by mycobacterial infections [90,112,113].
IRIS associated HIV-KS
Most HIV-seropositive subjects with KS do not demon-
strate HHV-8-specific cytotoxic T lymphocyte response.
This lack of HHV-8-specific cellural immune response
during HIV infection is a contributory factor in the devel-
opment of HIV-KS. The decline in the incidence of HIV-
KS, and the regression of KS in some HIV-seropositive
subjects after the introduction of HAART, suggests that
some general improvement in immunity and in the recov-
ery of HHV-8-specific, MHC class I-restricted cytotoxic
CD8+ T cell response could be important in the control of
HHV-8 replication [114,115]. The CD4+ and CD8+ T cells
that increase shortly after the introduction of HAART are
memory cells. It is probable that in HIV-seropositive sub-
jects who are commonly latently or subclinically coin-
fected with HHV-8, the HHV-8-specific cytotoxic T cells
lodge in sites of HHV-8 subclinical infection, or in sites of
established KS lesions. In most of HIV-seropositive sub-
jects, these CD8+ T cells will be protective and will control
HHV-8 replication and spread, thus reducing the inci-
dence of new KS lesions, and at times bringing about
regression in established KS lesions. However in a minor-
ity of HIV-seropositive subjects with subclinical HHV-8
infection, or with established KS, such an immune
response may be dysregulated and accompanied by an
intensified HHV-8-specific inflammatory response para-
doxically causing a worsening of KS and as a consequence,
the development of IRIS-KS [112].
There could be other mechanisms that may be involved in
the pathogenesis of IRIS-KS. As part of the immune resto-
ration after HAART, there is a shift in the cytokine profile
from the Th-2 to the Th-1 type. Th-1 cytokines have the
capacity to reactivate latent HHV-8 in blood and tissue
cells, and as a consequence, HHV-8 can spread to unin-
fected endothelial cells. Perhaps in a subset of HIV-serop-
ositive subjects, the restored HHV-8-specific immune
response following HAART is ineffective in controlling the
increased HHV-8 antigens in blood and tissue cells, and as
a result, paradoxically promotes the development of IRIS-
KS.
Because of the inability of the immune response to con-
trol the HHV-8 infection, two processes may occur in par-
allel; the development of an exaggerated
immunoinflammatory reaction characterized by the
increased production of inflammatory cytokines in order
to combat HHV-8; and secondly, the increase in the HHV-
8 load in the tissues through autocrine and paracrine
mechanisms increase the production of inflammatory
cytokines, chemokines and growth factors. Together these
processes upregulate the expression of αvβ3 and α5β1, and
MMPs that induce the IRIS-KS angioproliferation and
tumourigenesis [55]. In this context, HIV Tat protein and
a profound state of immunosuppression do not signifi-
cantly affect the development of IRIS-KS.
Bower et al. [33], reported that 10 of 150 (6.6%) HAART-
naïve HIV-seropositive subjects with KS either developed
new KS lesions or exhibited rapid progression of existingInfectious Agents and Cancer 2008, 3:1 http://www.infectagentscancer.com/content/3/1/1
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KS lesions within 2 months of starting HAART. These sub-
jects had a significantly higher CD4+ T cell count at the
time of IRIS-KS diagnosis and a higher frequency of KS-
associated oedema than HIV-seropositive subjects with KS
who did not develop IRIS.
Summary
The clinical course of HIV-KS is unpredictable. For some
HIV-seropositive subjects, KS is a mild disease, while for
others it may be rapidly progressive and aggressive.
Regression of HIV-KS lesions and a substantial decrease in
the incidence of HIV-KS occur after the introduction of
HAART. However, a small subset of HIV-seropositive sub-
jects with a low CD4 + T cell count at the time of HAART
initiation, may develop IRIS associated HIV-KS shortly
thereafter.
IRIS-KS is not a specific entity but it is a phenomenon
which can be recognized by certain well defined circum-
stances: the presence of low CD4+ T cell counts at the time
of introduction of HAART; a temporal relationship
between rapid clinical progression of KS and the develop-
ment of new KS lesions usually of about 8 weeks (though
this period may range from 3 weeks to 22 weeks) after the
initiation of HAART; and the suppression of HIV load and
restoration of CD4+ T cell count.
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